Show simple item record

Results of the dinutuximab beta, bevacizumab, irinotecan and topotecan randomisations of the beacon-neuroblastoma Phase 2 trial by itcc and siopen

dc.contributor.authorMoreno, L.
dc.contributor.authorWeston, R.
dc.contributor.authorOwens, C.
dc.contributor.authorGray, J.
dc.contributor.authorBarone, G.
dc.contributor.authorValteau-Couanet, D.
dc.contributor.authorSimon, A. R. S.
dc.contributor.authorMakin, Guy
dc.contributor.authorVaidya, S.
dc.contributor.authorGambart, M.
dc.contributor.authorCastel, V.
dc.contributor.authorVan Eijkelenburg, N.
dc.contributor.authorNysom, K.
dc.contributor.authorLaureys, G.
dc.contributor.authorLadenstein, R.
dc.contributor.authorCastellano, A.
dc.contributor.authorGerber, N.
dc.contributor.authorLaidler, J.
dc.contributor.authorKearns, P.
dc.contributor.authorWheatley, K.
dc.date.accessioned2022-11-30T10:21:22Z
dc.date.available2022-11-30T10:21:22Z
dc.date.issued2022en
dc.identifier.citationMoreno L, Weston R, Owens C, Gray J, Barone G, Valteau-Couanet D, et al. Results of the Dinutuximab Beta, Bevacizumab, Irinotecan and Topotecan Randomisations of the Beacon-Neuroblastoma Phase 2 Trial by Itcc and Siopen. Pediatric blood & cancer. 2022 Nov;69. PubMed PMID: WOS:000859203900215.en
dc.identifier.urihttp://hdl.handle.net/10541/625787
dc.language.isoenen
dc.titleResults of the dinutuximab beta, bevacizumab, irinotecan and topotecan randomisations of the beacon-neuroblastoma Phase 2 trial by itcc and siopenen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentValld’Hebron University Hospital,Paediatric Oncology And Haematology,Barcelona, Spain;en
dc.identifier.journalPediatric Blood & Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record